Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inetetamab + HB1801
- Development stage
- Discontinued
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
inetetamab + HB1801 is a hypothetical or non-standard combination regimen consisting of inetetamab (Cipterbin), a recombinant humanized anti-HER2 monoclonal antibody, and HB1801, an albumin-bound nanoparticle formulation of docetaxel. Inetetamab targets subdomain IV of the human epidermal growth factor receptor 2 (HER2) and features an engineered Fc region designed to enhance antibody-dependent cellular cytotoxicity (ADCC). HB1801 is a solvent-free, albumin-stabilized nanoparticle formulation of the microtubule-stabilizing taxane chemotherapy docetaxel, designed to improve safety and tolerability by avoiding the hypersensitivity-inducing solvents (polysorbate 80 and ethanol) used in conventional docetaxel. While both agents are developed by Chinese pharmaceutical companies (Sunshine Guojian and CSPC Pharmaceutical Group, respectively) and target HER2-positive cancers, there is no active clinical development or registered trial evaluating this specific combination; the actual clinical-stage combination under phase 3 development is anbenitamab (KN026) plus HB1801.
- Other names
- Cipterbin + HB1801
02
Targets
FCGR2B (Fc gamma receptor IIB)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on inetetamab + HB1801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inetetamab + HB1801.